Diadia
Our TechnologyResourcesAboutLoginBook a call

© 2026 Diadia. All rights reserved.

About UsOur TechnologyResearchResources
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions
About UsOur TechnologyResearchResources
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions

© 2026 Diadia. All rights reserved.

←Transparency Reports

cardiovascular · Mechanism Report

Does apolipoprotein B predict atherosclerotic cardiovascular risk better than LDL cholesterol?

ApoB, which stoichiometrically marks each atherogenic lipoprotein particle, more accurately predicts ASCVD risk than LDL-C, particularly when ApoB and LDL-C are discordant.

PlausibleJune 19, 202615 Sources

Reasoning Paths

Each route from condition to outcome carries a support score — the product of its edge weights. Select one to isolate it on the figure.

This is what AI claimed

Apolipoprotein B reflects the number of atherogenic lipoprotein particles (VLDL, IDL, LDL), and higher ApoB better predicts atherosclerotic cardiovascular risk than LDL cholesterol alone.

laying out figure…
3 of 5 paths supported
UnsupportedPlausibleSupported

How to read the figure

Evidence state

  • ●EstablishedStrong, replicated evidence.
  • ◐ModerateEvidence-informed; limited or moderate.
  • ◇PlausibleMechanistically coherent, not established.
  • ✕UnsupportedTested and not supported — link breaks.
  • ?MissingNo evidence either way — untested.

Node shapes

  • BiomarkerA measurable state — a lab value, hormone, or genetic factor.
  • ProcessA biological process, pathway, or mechanism step.
  • ConditionA condition, exposure, intervention, or symptom.
  • OutcomeThe endpoint the claim leads to.

Executive summary

The claim states that every VLDL, IDL, and LDL particle carries one ApoB molecule, so plasma ApoB directly counts atherogenic particles while LDL-C measures cholesterol content per particle. Mechanistic and cohort evidence show atherogenesis and clinical risk track with particle number (ApoB), meaning ApoB identifies elevated risk that LDL-C can miss in discordant cases such as hypertriglyceridemia or insulin resistance.

Verified conclusion

Biological and mechanistic basis

  • Stoichiometric precision: Every atherogenic lipoprotein particle—including very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), and low-density lipoprotein (LDL)—carries exactly one molecule of apolipoprotein B-100 (ApoB). This 1:1 stoichiometry remains intact throughout the lipolytic cascade as larger particles are remodeled into smaller, denser LDL particles.
  • Pathophysiologic driver: Atherogenesis is primarily driven by the physical entry and retention of ApoB-containing particles within the subendothelial space of the arterial wall. Because the cholesterol cargo per particle varies widely, measuring ApoB directly quantifies the number of circulating atherogenic vehicles, whereas LDL cholesterol (LDL-C) measures only the total cholesterol concentration within those vehicles.

Clinical evidence and predictive value

  • The discordance phenomenon: Large-scale prospective studies, including the UK Biobank, the Multi-Ethnic Study of Atherosclerosis (MESA), and the Korean Genome and Epidemiology Study (KoGES), demonstrate that when LDL-C and ApoB levels are discordant, atherosclerotic cardiovascular disease (ASCVD) risk tracks with ApoB rather than LDL-C.
  • Underestimation of risk: Individuals with low or "normal" LDL-C but elevated ApoB (often seen in insulin resistance, metabolic syndrome, or hypertriglyceridemia) face a significantly higher risk of myocardial infarction and subclinical plaque progression. Conversely, those with high LDL-C but low ApoB exhibit lower risk, demonstrating that LDL-C alone can fail to capture true atherogenic burden.

Bottom line

  • For a 53-year-old male, incorporating ApoB into clinical assessment offers a more precise evaluation of ASCVD risk than LDL-C alone. Because ApoB directly counts the atherogenic particles driving arterial plaque formation, it provides critical prognostic clarity, especially in cases of biomarker discordance.

References

  1. Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target — mdpi.com ↗
  2. Lipoprotein(a) and risk-weighted apolipoprotein B: a novel metric for atherogenic risk — pmc.ncbi.nlm.nih.gov ↗
  3. The extended lipid panel assay: a clinically-deployed high-throughput nuclear magnetic resonance method for the simultaneous measurement of lipids and Apolipoprotein B — lipidworld.biomedcentral.com ↗
  4. New and Emerging Therapeutic Targets for ApoB-Containing Particles Lowering. — ahajournals.org ↗
  5. Apolipoprotein B compared with low-density lipoprotein cholesterol in the atherosclerotic cardiovascular diseases risk assessment. — linkinghub.elsevier.com ↗
  6. ApoB100 and Atherosclerosis: What’s New in the 21st Century? — pmc.ncbi.nlm.nih.gov ↗
  7. Discordance among apoB, non–high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention — pmc.ncbi.nlm.nih.gov ↗
  8. Associations of LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B With Cardiovascular Disease Occurrence in Adults: Korean Genome and Epidemiology Study — pmc.ncbi.nlm.nih.gov ↗
  9. Discordance analysis for apolipoprotein and lipid measures for predicting myocardial infarction in statin-treated patients with coronary artery disease: a cohort study. — pmc.ncbi.nlm.nih.gov ↗
  10. Apolipoprotein B, Non-HDL Cholesterol, and LDL Cholesterol as Markers for Atherosclerotic Cardiovascular Disease Risk Assessment — annlabmed.org ↗
  11. Apolipoprotein B discordance with low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol in relation to coronary artery calcification in the Multi-Ethnic Study of Atherosclerosis (MESA). — pmc.ncbi.nlm.nih.gov ↗
  12. Effect of HDL disk and LDL dimer presence on lipoprotein particle number determination and subclassification — link.springer.com ↗
  13. Apt interpretation of comprehensive lipoprotein data in large-scale epidemiology: disclosure of fundamental structural and metabolic relationships — academic.oup.com ↗
  14. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. — pmc.ncbi.nlm.nih.gov ↗
  15. Achievement of Low-Density Lipoprotein Cholesterol Targets in Cardiac Rehabilitation: Impact of the 2019 ESC/EAS Dyslipidaemia Guidelines — mdpi.com ↗

See a full patient report verified like this

Book a walkthrough

Related Claims

Plausible10 sourcesAre F2-isoprostanes biomarkers of lipid peroxidation and does oxidized LDL contribute to atherosclerosis?→Plausible10 sourcesDo hs-CRP, Lp-PLA2, and myeloperoxidase reflect different cardiovascular risk signals?→